Tumor Evolution, Heterogeneity, and Therapy for Our Patients With Advanced Cancer: How Far Have We Come?

作者
Wafik S. El‐Deiry,Barry S. Taylor,Joel W. Neal
出处
期刊:American Society of Clinical Oncology educational book [American Society of Clinical Oncology]
卷期号:37 (37): e8-e15 被引量:23
标识
DOI:10.1200/edbk_175524
摘要

The clinical and molecular heterogeneity of various cancer types is well documented. In the era of precision oncology whereby molecular profiling of tumors is incorporated into clinical care, both intra- and intertumoral molecular and genetic heterogeneity have been described. Together, they impact patient treatment and outcomes. Host genetics and the tumor microenvironment impact on tumor evolution and heterogeneity through variations in immune cell infiltration, stromal variations, and selection pressures from hypoxia or nutrient stress, among others. Tumor progression and exposure to therapeutic agents lead to further molecular evolution and heterogeneity that is clinically relevant. Moreover, tumors that evolve after diagnosis and as a function of therapy generally become more aggressive and refractory to available therapeutics, including targeted agents and immunotherapy. The evolving clinical and molecular heterogeneity of patient tumors can be explored with various clinical and research-based specimens and testing such as pre- and post-treatment biopsies; serial liquid biopsies; single cell analysis; PDX and organoid models; anatomic, functional, and molecular imaging; and rapid postmortem studies. Other factors that influence tumor heterogeneity include immune checkpoints, cancer stem cells, therapy-acquired resistance mechanisms that may occur through secondary mutations, and adaptive responses. Modern technologic advances for tumor characterization provide opportunities to understand tumor evolution and its impact on clinical outcomes to improve therapeutic regimens. Characterization of novel targets and development of effective therapeutics are needed to target heterogeneity and the evolution of resistance mechanisms.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
lzh完成签到,获得积分10
刚刚
张清越发布了新的文献求助10
1秒前
adai007发布了新的文献求助10
1秒前
dywen完成签到,获得积分10
1秒前
未知数完成签到,获得积分10
1秒前
Cjl10610的应助被A_媛采纳,获得30
2秒前
2秒前
橘子发布了新的文献求助10
2秒前
小象有点忙完成签到,获得积分10
2秒前
sdfwsdfsd完成签到,获得积分10
2秒前
777完成签到,获得积分10
3秒前
3秒前
3秒前
XD完成签到,获得积分10
3秒前
回来完成签到,获得积分0
3秒前
Cassiopiea19完成签到,获得积分10
4秒前
番茄炒蛋完成签到,获得积分10
4秒前
思源的应助被快乐友儿采纳,获得10
4秒前
杨坤完成签到,获得积分20
5秒前
溯源完成签到,获得积分10
5秒前
牛牛小天使完成签到,获得积分10
5秒前
樊小胖完成签到,获得积分10
5秒前
Orange的应助被三月abc采纳,获得10
5秒前
yang2pu完成签到,获得积分10
5秒前
taotaowulongcha完成签到,获得积分10
6秒前
灵巧的飞雪完成签到 ,获得积分10
6秒前
sxw完成签到,获得积分10
6秒前
6秒前
村长热爱美丽完成签到 ,获得积分10
6秒前
7788完成签到,获得积分10
6秒前
雪落你看不见完成签到,获得积分10
6秒前
7秒前
7秒前
854fycchjh完成签到,获得积分10
7秒前
美满的书南完成签到,获得积分10
7秒前
一蓝完成签到,获得积分10
8秒前
米米发布了新的文献求助10
8秒前
xiaopang完成签到,获得积分10
9秒前
CO2发布了新的文献求助10
9秒前
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180488
求助须知:如何正确求助?哪些是违规求助? 9570437
关于积分的说明 21812406
捐赠科研通 7776516
什么是DOI,文献DOI怎么找? 3433277
关于科研通互助平台的介绍 2557516
邀请新用户注册赠送积分活动 2479162